With investors increasingly focusing on ESG topics, you might think that being a Tech for Good company would help attract funding. This is not always the case, says Marc Gitzinger, CEO of...
With investors increasingly focusing on ESG topics, you might think that being a Tech for Good company would help attract funding. This is not always the case, says Marc Gitzinger, CEO of Bioversys, which is developing new medicines for severe life-threatening bacterial infections that are resistant to antibiotics.
In episode five, Gitzinger says the biotech industry still focuses mainly on financial returns and calls on impact investors to pay more attention to the topic of equitable health to ensure access and proper control of good quality drugs throughout the world.
Gitzinger discusses how he defines success, including the importance of generating financial returns for the investors who have believed in the technology and backed the business.
August 30, 2024 • by Julia Binder, Manuel Braun in Videos • 8 min read
Julia Binder and Manuel Braun delve into why a circular approach to business can help build more resilience and boost profitability....
YouTubeAugust 23, 2024 • by Katharina Lange in Videos • 7 min read
Understanding generational differences can help unlock the potential of your entire workforce....
YouTubeThe boundary between the physical and digital worlds is dissolving, says Joseph Bradley, CEO of TONOMUS. Harnessing data's power while managing risks is crucial for an integrated future....
YouTube
Share